Personalized dietary management in metabolic associated steatotic liver disease
Introduction Diet as a non-pharmacological therapeutic intervention is defined as the structured and personalized modification (based on physical characteristics and nutritional needs according to pathologies) of eating habits with the aim of improving the clinical and metabolic status of patients. Focusing on metabolic-associated steatotic liver disease (MASLD), nutritional intervention is the fundamental pillar of clinical […]
Pharmacological treatment of steatotic liver disease associated with metabolic dysfunction
Introduction Metabolic dysfunction-associated steatotic liver disease (MASLD) ranges from simple steatosis, metabolic dysfunction-associated steatohepatitis (MASH), or cirrhosis to even hepatocellular carcinoma1. Hepatic fibrosis is the main determinant of MASLD progression. Advanced fibrosis (stage ≥ 3) is associated with a higher risk of developing hepatic decompensation (ascites, variceal bleeding, and hepatic encephalopathy), need for liver transplantation, […]
Endoscopic options and bariatric surgery in metabolic dysfunction-associated steatotic liver disease
Introduction First-line treatment for metabolic dysfunction-associated steatotic liver disease (MASLD) consists of intensive lifestyle changes, with the goal of achieving weight loss greater than 7-10% to obtain histological improvement1. However, it has been shown that less than 10% of patients achieve these goals in a sustained manner with conventional dietary and medical therapy, which underscores […]